CEL-SCI (CVM) Competitors $4.51 -0.60 (-11.74%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.40 -2.12 (-46.90%) As of 06:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CVM vs. SNTI, ZURA, CLLS, CLYM, IZTC, OCX, ADAG, CRVO, TCRX, and IMABShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Senti Biosciences (SNTI), Zura Bio (ZURA), Cellectis (CLLS), Climb Bio (CLYM), Invizyne Technologies (IZTC), OncoCyte (OCX), Adagene (ADAG), CervoMed (CRVO), TScan Therapeutics (TCRX), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Senti Biosciences Zura Bio Cellectis Climb Bio Invizyne Technologies OncoCyte Adagene CervoMed TScan Therapeutics I-Mab CEL-SCI (NYSE:CVM) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation. Do institutionals and insiders hold more shares of CVM or SNTI? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 9.9% of CEL-SCI shares are owned by company insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to CVM or SNTI? In the previous week, CEL-SCI had 5 more articles in the media than Senti Biosciences. MarketBeat recorded 8 mentions for CEL-SCI and 3 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.00 beat CEL-SCI's score of -0.02 indicating that Senti Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CEL-SCI 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, CVM or SNTI? CEL-SCI has higher earnings, but lower revenue than Senti Biosciences. CEL-SCI is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$0.42-10.74Senti Biosciences$2.56M32.81-$71.06M-$10.84-0.30 Do analysts recommend CVM or SNTI? Senti Biosciences has a consensus price target of $12.00, indicating a potential upside of 272.67%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Senti Biosciences is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, CVM or SNTI? CEL-SCI has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Is CVM or SNTI more profitable? Senti Biosciences' return on equity of -154.84% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -238.05% -104.65% Senti Biosciences N/A -154.84%-77.42% Does the MarketBeat Community prefer CVM or SNTI? Senti Biosciences received 5 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 45.45% of users gave Senti Biosciences an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformCEL-SCIOutperform VotesNo VotesUnderperform Votes27100.00% Senti BiosciencesOutperform Votes545.45% Underperform Votes654.55% SummarySenti Biosciences beats CEL-SCI on 12 of the 16 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$410.58M$2.93B$5.38B$19.42BDividend YieldN/A1.71%5.21%3.83%P/E Ratio-9.4030.5026.8034.23Price / SalesN/A400.15389.5534.85Price / CashN/A168.6838.2517.51Price / Book30.073.286.804.69Net Income-$26.92M-$72.17M$3.23B$1.02B7 Day Performance-35.01%2.96%1.53%-1.74%1 Month Performance-44.67%3.25%10.05%7.46%1 Year Performance-88.35%-28.29%16.75%3.96% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCIN/A$4.51-11.7%N/A-88.5%$410.58MN/A-9.4043News CoverageHigh Trading VolumeSNTISenti Biosciences1.6894 of 5 stars$3.26flat$12.00+268.1%-14.7%$85.02M$2.56M-0.214ZURAZura Bio2.859 of 5 stars$1.24+2.5%$14.33+1,055.9%-81.3%$84.79MN/A-2.343News CoverageAnalyst RevisionGap UpCLLSCellectis2.763 of 5 stars$1.51-4.4%$7.00+363.6%-48.5%$83.93M$41.51M-1.16290CLYMClimb Bio2.5447 of 5 stars$1.24+4.2%$10.00+706.5%N/A$83.79MN/A-0.589Positive NewsAnalyst RevisionGap UpIZTCInvizyne TechnologiesN/A$13.01+4.0%N/AN/A$81.34MN/A0.00N/AOCXOncoCyte2.414 of 5 stars$2.81-2.1%$4.42+57.2%+8.9%$80.36M$1.88M-0.64120Analyst ForecastGap DownADAGAdagene2.3111 of 5 stars$1.70+6.2%$8.00+370.9%-35.9%$80.04M$103,204.000.00260Positive NewsGap UpCRVOCervoMed3.3162 of 5 stars$9.10+7.2%$27.63+203.6%-56.2%$79.20M$7.14M-4.484TCRXTScan Therapeutics3.9397 of 5 stars$1.37+7.9%$8.50+520.4%-85.8%$77.53M$4.42M-1.29100Positive NewsInsider TradeIMABI-Mab3.1896 of 5 stars$0.95+7.4%$5.50+482.0%-46.4%$77.02M$3.27M0.00380News Coverage Related Companies and Tools Related Companies Senti Biosciences Competitors Zura Bio Competitors Cellectis Competitors Climb Bio Competitors Invizyne Technologies Competitors OncoCyte Competitors Adagene Competitors CervoMed Competitors TScan Therapeutics Competitors I-Mab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
